Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000798255 | SCV000937860 | uncertain significance | MHC class II deficiency | 2022-08-16 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 163 of the CIITA protein (p.Pro163Thr). This variant is present in population databases (rs555184617, gnomAD 0.2%). This variant has not been reported in the literature in individuals affected with CIITA-related conditions. ClinVar contains an entry for this variant (Variation ID: 644359). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV003279073 | SCV004008483 | uncertain significance | Inborn genetic diseases | 2023-04-19 | criteria provided, single submitter | clinical testing | The c.487C>A (p.P163T) alteration is located in exon 7 (coding exon 7) of the CIITA gene. This alteration results from a C to A substitution at nucleotide position 487, causing the proline (P) at amino acid position 163 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV000798255 | SCV001462164 | uncertain significance | MHC class II deficiency | 2020-03-17 | no assertion criteria provided | clinical testing |